Completed PHASE3 INTERVENTIONAL NCT00035321

The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression

The Study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features

Sponsor: Eli Lilly and Company

Updated 6 times since 2017 Last updated: Jul 21, 2006 Started: Apr 30, 2002 Completion: Jul 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00035321, this PHASE3 trial focuses on Major Depressive Disorder and remains completed. Sponsored by Eli Lilly and Company, it has been updated 6 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Baltimore, United States , Chicago, United States , Clementon, United States , Columbia, United States , Coral Springs, United States , Dallas, United States , Dayton, United States , Glen Burnie, United States , Kingston, Canada and 22 more locations